Monokine induced by interferon-γ (MIG/CXCL9) is derived from both donor and recipient sources during rejection of class II major histocompatibility complex disparate skin allografts

American Journal of Pathology

Volumn 174, Issue 6, 2009, Pages 2172-2181

  Auerbach, Michael B ^a   Shimoda, Naohiko ^a   Amano, Hiroyuki ^a   Rosenblum, Joshua M ^a,b   Kish, Danielle D ^a   Farber, Joshua M ^c   Fairchild, Robert L ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL9 CHEMOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACUTE GRAFT REJECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DONOR; GENE DELETION; GRAFT REJECTION; GRAFT SURVIVAL; MOUSE; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; SKIN ALLOGRAFT; T LYMPHOCYTE;

EID: 67049164005     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080516     Document Type: Article

References (31)

1. Hall B: Cells mediating allograft rejection. Transplantation 1991, 51:1141-1151
2. Rosenberg AS, Singer A: Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol 1992, 10:333-358
3. Fuggle SV, Sanderson JB, Gray DWR, Richardson A, Morris PJ: Variation in expression of endothelial adhesion molecules in pretransplant and transplanted kidneys: correlation with intragraft events. Transplantation 1993, 55:117-123 (Pubitemid 23033956)
4. Pelletier RP, Ohye RG, VanBuskirk AM, Sedmak DD, Kincade P, Ferguson RM, Orosz CG: Importance of endothelial VCAM-1 for inflammatory leukocytic infiltration in vivo. J Immunol 1992, 149:2473-2481
5. von Andrian U, Mackay CR: T-cell function and migration. N Engl J Med 2000, 343:1020-1034
6. Nicolls MR, Gill RG: LFA-1 (CD11a) as a therapeutic target. Am J Transplant 2006, 6:27-36 (Pubitemid 43382197)
7. Isobe M, Yagita H, Okumura K, Ihara A: Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992, 255:1125-1129
8. Zhang Q-W, Kish DD, Fairchild RL: Absence of allograft ICAM-1 attenuates alloantigen-specific T cell priming, but not primed T cell trafficking into the graft, to mediate acute rejection. J Immunol 2003, 170:5530-5537 (Pubitemid 36617841)
9. Hancock WW, Wang I, Ye O, Han R, Lee I: Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003, 15:479-486 (Pubitemid 37130185)
10. Gao W, Faia KL, Csizmadia V, Smiley ST, Soler D, King JA, Danoff TM, Hancock WW: Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001, 72:1199-1205 (Pubitemid 33026595)
11. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, Smiley ST, Ling M, Gerard NP, Gerard C: Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000, 192:1515-1520 (Pubitemid 30953889)
12. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguir P, Farber JM: Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995, 182:1301-1314
13. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B: Chemokine receptor specific for IP-10 and Mig: structure function and expression in activated T-lymphocytes. J Exp Med 1996, 184:963-969 (Pubitemid 26313554)
14. Kondo T, Novick AC, Toma H, Fairchild RL: Induction of chemokine gene expression during allogeneic skin graft rejection. Transplantation 1996, 61:1750-1757 (Pubitemid 26242016)
15. Miura M, Morita K, Kobayashi H, Hamilton TA, Burdick MA, Strieter RM, Fairchild RL: Monokine induced by IFN-γ is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol 2001, 167:3494-3504 (Pubitemid 32852596)
16. Fahmy ND, Yamani MH, Starling RX, Ratliff NB, Young JB, McCarthy PM, Feng J, Novick AC, Fairchild RL: Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 2003, 75:72-78 (Pubitemid 36139698)
17. Melter M, Exeni A, Reinders MEJ, Fang JC, McMahon G, Ganz P, Hancock WW, Briscoe DM: Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001, 104:2558-2564 (Pubitemid 33104793)
18. Koga S, Auerbach MD, Engeman TM, Novick AC, Toma H, Fairchild RL: T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-γ-induced chemokine Mig. J Immunol 1999, 163:4878-4885 (Pubitemid 29501252)
19. Kobayashi H, Novick AC, Toma H, Fairchild RL: Chronic antagonism of Mig inhibits cellular infiltration and promotes survival of class II MHC disparate skin allografts. Transplantation 2002, 74:387-395 (Pubitemid 34894290)
20. Farber JM: Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997, 61:246-257 (Pubitemid 27149903)
21. Park MK, Amichay D, Love P, Wick E, Liao F, Grinberg A, Rabin RL, Zhang HH, Gebeyehu S, Wright TM, Iwasaki A, Weng Y, DeMartino JA, Elkins KL, Farber JM: The CXC chemokine murine monokine induced by IFN-γ (CXC chemokine ligand 9) is made by APCs, targets lymphocytes including activated B cells, and supports antibody responses to a bacterial pathogen in vivo. J Immunol 2002, 169:1433-1443 (Pubitemid 34811943)
22. Billingham RE, Medawar PB: The technique of free skin grafting in mammals. J Exp Biol 1951, 28:385-402
23. Dvorak HF, Mihm Jr MC, Dvorak AM, Barnes BA, Manseau EJ, Galli SJ: Rejection of first-set skin allografts in man, the microvasculature is the critical target of the immune response. J Exp Med 1979, 150:322-337 (Pubitemid 9220319)
24. Jooste SV, Colvin RB, Soper WD, Winn HJ: The vascular bed as the primary target in the destruction of skin grafts by antiserum. I. Resistance of freshly placed xenografts of skin to antiserum. J Exp Med 1981, 154:1319-1331
25. Jooste SV, Colvin RB, Winn HJ: The vascular bed as the primary target in the destruction of skin grafts by antiserum. II. Loss of sensitivity to antiserum in long-term xenografts of skin. J Exp Med 1981, 154:1332-1341 (Pubitemid 12235182)
26. Abdi R, Smith RN, Makhlouf L, Najafian N, Luster AD, Auchincloss Jr H, Sayegh MH: The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 2002, 51:2489-2495 (Pubitemid 34827398)
27. Dvorak HF, Mihm Jr MC., Dvorak AM, Barnes BA, Galli SJ: The microvasculature is the critical target of the immune response in vascularized skin allograft rejection. Transplantation 1980, 74:280-284 (Pubitemid 10034220)
28. Watarai Y, Paolone D, Koga S, Tannenbaum C, Hamilton TA, Fairchild RL: Intragraft chemokine expression during rejection of skin grafts with multiple minor histocompatibility differences. J Immunol 2000, 164:6027-12033
29. Valujskikh A, Lantz O, Celli S, Matzinger P, Heeger PS: Cross-primed CD8 T cells mediate graft rejection via a distinct effector pathway. Nat Immunol 2002, 3:844-851 (Pubitemid 35049435)
30. Nozaki T, Amano H, Bickerstaff A, Orosz CG, Novick AC, Tanabe K, Fairchild RL: Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol 2007, 179:5238-5245
31. Whiting D, Hsieh G, Yun JJ, Banerji A, Yao W, Fishbein M, Belperio J, Strieter RM, Bonavida B, Ardehali A: Chemokine monokine induced by IFN-γ/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol 2004, 172:7417-7424 (Pubitemid 38747603)